C
Carles X. Raventós
Researcher at Hebron University
Publications - 33
Citations - 1179
Carles X. Raventós is an academic researcher from Hebron University. The author has contributed to research in topics: Prostate cancer & Androgen deprivation therapy. The author has an hindex of 17, co-authored 30 publications receiving 1114 citations. Previous affiliations of Carles X. Raventós include University of Barcelona.
Papers
More filters
Journal ArticleDOI
Redefining clinically significant castration levels in patients with prostate cancer receiving continuous androgen deprivation therapy.
Juan Morote,Anna Orsola,Jacques Planas,Enrique Trilla,Carles X. Raventós,Lluís Cecchini,Roberto Catalán +6 more
TL;DR: The lowest testosterone castration level with clinical relevance in medically castrated patients with prostate cancer was 32 ng/dl, and maximal androgen blockade provided a significantly longer survival free of androgen independent progression in those with breakthrough increases greater than 50 ng/DL.
Journal ArticleDOI
Prevalence of osteoporosis during long-term androgen deprivation therapy in patients with prostate cancer.
Juan Morote,Jacques Planas Morin,Anna Orsola,Jose M. Abascal,Carles Salvador,Enrique Trilla,Carles X. Raventós,Lluís Cecchini,Encabo G,Jaume Reventós +9 more
TL;DR: The prevalence of osteoporosis seemed high in hormone-naive patients with prostate cancer, and it increased to more than 80% after 10 years ofADT, and clinicians should be aware of the impact of ADT on BMD to prevent bone mass loss.
Journal ArticleDOI
Bone Mineral Density Changes in Patients With Prostate Cancer During the First 2 Years of Androgen Suppression
Juan Morote,Anna Orsola,Jose M. Abascal,Jacques Planas,Enrique Trilla,Carles X. Raventós,Lluís Cecchini,Encabo G,Jaume Reventós +8 more
TL;DR: Bone mineral density decreases during the first 24 months of androgen suppression with the most relevant effect occurring in the first year.
Journal ArticleDOI
Comparison of Percent Free Prostate Specific Antigen and Prostate Specific Antigen Density as Methods to Enhance Prostate Specific Antigen Specificity in Early Prostate Cancer Detection in Men With Normal Rectal Examination and Prostate Specific Antigen Between 4.1 and 10 ng./ml.
Juan Morote,Carles X. Raventós,José A. Lorente,M.A. López-Pacios,G. Encabo,I. de Torres,J. Andreu +6 more
TL;DR: Although both methods could minimize unnecessary biopsies in men with normal digital rectal examination and PSA serum level between 4.1 and 10 ng./ml.
Journal ArticleDOI
Clinical Efficacy of Bone Alkaline Phosphatase and Prostate Specific Antigen in the Diagnosis of Bone Metastasis in Prostate Cancer
TL;DR: The clinical use of bone alkaline phosphatase enzyme determined by radioimmunoassay and PSA measurement for the diagnosis of bone metastases and progression of prostate cancer is recommended because of the good sensitivity and specificity.